Myovant Sciences (NYSE: MYOV), a healthcare company focused on
redefining care for women and for men, today announced financial
results for the second quarter of fiscal year 2021 and other
corporate updates.
“During our second fiscal quarter, we continued to
make significant progress on the commercial launches of ORGOVYX and
MYFEMBREE, enabling our mission to redefine care and positioning
Myovant for long-term success. ORGOVYX launch momentum continued to
build with net product revenues of $18.7 million, representing 78%
sequential growth compared to the previous quarter, and reflecting
increased patient and clinician demand for the differentiated
clinical profile of ORGOVYX. Our team remains passionate about
improving the lives of men with advanced prostate cancer by
providing the first and only approved oral medication capable of
rapidly and profoundly reducing testosterone levels without an
initial hormonal surge,” said David Marek, Chief Executive Officer
of Myovant Sciences, Inc.
Mr. Marek added, “We are also encouraged by the
early launch progress for MYFEMBREE as we bring this important new
treatment option to women in the U.S. with symptomatic uterine
fibroids. Sequential growth since launch across key metrics,
including cumulative patients on therapy and enrollments to the
MYFEMBREE patient support hub, coupled with increasing prescriber
awareness and recent improvements in payer coverage gives us
confidence that MYFEMBREE is being positioned for long-term
success. Additionally, the FDA in August lifted the partial
clinical hold on the Phase 3 SERENE study following certain
protocol amendments, and in September, accepted our supplemental
New Drug Application seeking to extend approval of MYFEMBREE to
include women with endometriosis, with a decision expected by May
6, 2022.”
Second Fiscal Quarter 2021 and Recent
Corporate Updates
ORGOVYX (relugolix 120 mg)
- Second fiscal quarter
2021 net product revenues for ORGOVYX in the U.S. were $18.7
million, driven by increased prescriber demand.
- Approximately 1,500
treatment centers have prescribed ORGOVYX to approximately 8,000
patients on free and commercial drug, estimated through
September 30, 2021. The cumulative number of estimated
patients initiating ORGOVYX therapy has continued to increase
steadily in each successive month since launch.
- As of October 1, 2021,
Myovant achieved 76% commercial coverage and 81% Medicare Part D
coverage for ORGOVYX. Myovant achieved broad coverage for ORGOVYX
in advance of its calendar year-end 2021 goal but continues to
engage in negotiations with payors yet to make a coverage decision.
Myovant expects broad commercial and Part D coverage for ORGOVYX to
continue in calendar-year 2022.
MYFEMBREE (relugolix 40 mg, estradiol 1.0 mg, and
norethindrone acetate 0.5 mg)
- Second fiscal quarter
2021 net product revenues for MYFEMBREE in the U.S. were $0.6
million, primarily reflecting a continuation of initial inventory
stocking. Modest demand-driven re-orders to replenish launch
inventories began in September 2021.
- Approximately 600
patients have initiated treatment through September 30, 2021,
including patients on commercial drug and free drug programs,
excluding patients utilizing product samples.
- As of October 8, 2021,
Myovant achieved 61% commercial coverage for MYFEMBREE. Myovant
continues to engage in coverage negotiations with key commercial
payors yet to make a coverage decision and remains on track to
achieve its goal of broad coverage within one year of launch.
- In October 2021,
Myovant and Pfizer presented data from clinical studies of
MYFEMBREE at the American Society for Reproductive Medicine (ASRM)
2021 Congress, including results of the Phase 3 LIBERTY randomized
withdrawal study, which was designed to evaluate the efficacy and
safety of relugolix combination therapy for up to two years in
women with heavy menstrual bleeding associated with uterine
fibroids, and was designated an ASRM Prize Paper. Additional data
presentations at ASRM included data from the SPIRIT 1 and 2 studies
of women with pain associated with endometriosis as well as pooled
safety and tolerability data from the LIBERTY and SPIRIT clinical
programs.
- In September 2021, the
U.S. Food and Drug Administration (FDA) accepted Myovant’s
supplemental New Drug Application (sNDA) for MYFEMBREE for the
management of moderate to severe pain associated with
endometriosis, setting a target action date of May 6, 2022. FDA
approval of MYFEMBREE for this indication would trigger a $100.0
million regulatory milestone payment from Pfizer.
- In August 2021, the
FDA informed Myovant that the partial clinical hold for the Phase 3
SERENE study evaluating MYFEMBREE for the prevention of pregnancy
was lifted following study protocol amendments. The amended SERENE
study protocol will evaluate the contraceptive efficacy of
MYFEMBREE in women with heavy menstrual bleeding associated with
uterine fibroids or endometriosis-associated pain who are 18 to 50
years of age and at risk for pregnancy, and includes bone mineral
density monitoring for patients during and after treatment. Patient
screening with this updated protocol began in September 2021, with
initial patients dosed in October 2021.
- The FDA approval of
MYFEMBREE in May 2021 for the management of heavy menstrual
bleeding associated with uterine fibroids in the U.S. triggered a
$100.0 million regulatory milestone payment from Pfizer, which
Myovant received in July 2021.
RYEQO (relugolix 40 mg, estradiol 1.0 mg, and
norethindrone acetate 0.5 mg)
- On July 16, 2021 and
August 9, 2021, the European Commission (EC) and the Medicines and
Healthcare products Regulatory Agency, respectively, approved RYEQO
for the treatment of moderate to severe symptoms of uterine
fibroids in adult women of reproductive age. RYEQO is the first and
only long-term, once-daily oral treatment for uterine fibroids with
no limitation on its duration of use approved in the European Union
and the United Kingdom. Gedeon Richter (Richter), Myovant’s
commercialization partner for RYEQO in Europe and certain other
international markets, launched RYEQO in seven countries since
these regulatory approvals.
- The approval of RYEQO
for the uterine fibroids indication by the EC triggered a $15.0
million regulatory milestone payment from Richter, which Myovant
received and recorded as Richter license and milestone revenue in
its second fiscal quarter of 2021.
Pfizer Option
- On October 22, 2021,
Myovant was notified by Pfizer of their decision to decline the
exclusive option for international commercialization and
development rights (excluding Canada and certain Asian countries)
to relugolix in oncology, as offered under the December 2020
collaboration agreement between the two companies. Pfizer’s
decision is based on their assessment of their current strategic
investment priorities in international markets and does not impact
the companies’ collaboration in the U.S. and Canada for ORGOVYX and
MYFEMBREE. Myovant is currently assessing partnership opportunities
with multiple interested parties, focusing on potential partners
with a European commercial presence in urology or oncology.
Executive Appointments
- On September 7, 2021,
Uneek Mehra was appointed Chief Financial and Business Officer of
Myovant Sciences, Inc. Concurrent with this appointment, Mr. Mehra
was also appointed Principal Financial Officer of Myovant Sciences
Ltd.
Expected Upcoming Milestones
- FDA submission of the
Phase 3 LIBERTY randomized withdrawal study results for MYFEMBREE
in women with uterine fibroids is expected by the end of calendar
year 2021 or in the first quarter of calendar year 2022.
- Two-year data from the
SPIRIT long-term extension study of MYFEMBREE in women with
endometriosis-associated pain is expected in the first quarter of
calendar year 2022.
- FDA decision for the
MYFEMBREE sNDA seeking approval for the management of moderate to
severe pain associated with endometriosis is expected by its May 6,
2022 target action date. FDA approval of MYFEMBREE for this
indication would trigger a $100.0 million regulatory milestone
payment from Pfizer.
- EC decision on the
advanced prostate cancer Marketing Authorisation Application is
expected in mid-calendar year 2022.
- European Medicines
Agency regulatory submission for RYEQO for the treatment of women
with endometriosis-associated pain is expected in calendar year
2022. Richter will be the sponsor.
Second Fiscal Quarter 2021 Financial
Summary
Total revenues for the three
months ended September 30, 2021 were $77.9 million. There were no
such revenues in the three months ended September 30, 2020.
- Product
revenue, net from sales of ORGOVYX and MYFEMBREE in the
U.S. for the three months ended September 30, 2021 were $18.7
million and $0.6 million, respectively. For the three months ended
September 30, 2021 product revenue, net also includes revenues
related to product supply to Richter of $1.7 million, as well
as royalties on net sales of RYEQO in Richter’s Territory of less
than $0.1 million. There was no such revenue recorded in the
comparable prior year period.
- Pfizer
collaboration revenue for the three months ended September
30, 2021 was $25.2 million, reflecting the partial recognition of
the upfront payment Myovant received from Pfizer in December 2020
and of the regulatory milestone payment that was triggered upon the
FDA approval of MYFEMBREE for the management of heavy menstrual
bleeding associated with uterine fibroids in May 2021. There was no
such revenue recorded in the comparable prior year period.
- Richter
license and milestone revenue for the three months ended
September 30, 2021 was $31.7 million, reflecting recognition of the
remaining $16.7 million of previously deferred revenue as a result
of Myovant’s delivery of the remaining substantive relugolix
combination tablet data packages to Richter pursuant to the Richter
Development and Commercialization Agreement, and the $15.0 million
regulatory milestone payment triggered by the EC approval of RYEQO
for the uterine fibroids indication. There was no such revenue in
the three months ended September 30, 2020.
Cost of product revenue for the
three months ended September 30, 2021 was $2.6 million related to
the cost of goods sold and royalty expense payable to Takeda
pursuant to the Takeda License Agreement. There were no such
amounts recognized in the comparable prior year period.
Collaboration expense to Pfizer
for the three months ended September 30, 2021, was $8.6 million,
reflecting Pfizer’s 50% share of net profits from sales of ORGOVYX
and MYFEMBREE in the U.S., pursuant to the Pfizer Collaboration and
License Agreement. There were no such amounts recognized in the
comparable prior year period.
Research and development (R&D)
expenses for the three months ended September 30, 2021, were $26.3
million compared to $40.5 million for the comparable prior year
period. The decrease in R&D expenses reflects cost share
reimbursements from Pfizer for certain R&D expenses and a
reduction in clinical study costs as a result of the completion and
wind down of Myovant’s Phase 3 LIBERTY, HERO, and SPIRIT studies.
This decrease was partially offset by an increase in medical
affairs personnel expenses to support the U.S. launches of ORGOVYX
and MYFEMBREE.
Selling, general and administrative
(SG&A) expenses for the three months ended September
30, 2021, were $58.8 million compared to $31.3 million for the
comparable prior year period. The increase was primarily due to
higher expenses to support the ORGOVYX and MYFEMBREE U.S. launches,
including higher personnel-related costs primarily due to the
hiring of Myovant’s commercial operations, marketing, and market
access teams, as well as the oncology and women’s health sales
forces, and higher general overhead expenses to support Myovant’s
organizational growth.
Interest expense was $3.5 million
for the three months ended September 30, 2021, compared to $2.1
million for the comparable prior year period. The increase in
interest expense was primarily driven by the higher balance under
Myovant’s loan agreement with Sumitomo Dainippon Pharma (Sumitomo
Dainippon Pharma Loan Agreement) and $0.6 million of accretion of
the financing component of the cost share advance from Pfizer.
Foreign exchange gain for the
three months ended September 30, 2020 was $6.7 million, primarily
the result of the impact of fluctuations in the foreign currency
exchange rate between the Swiss franc and the U.S. dollar on
Myovant’s outstanding balance under the Sumitomo Dainippon Pharma
Loan Agreement. As a result of a change in the functional currency
of Myovant’s wholly-owned subsidiary in Switzerland, Myovant
Sciences GmbH, from the Swiss franc to the U.S. dollar in December
2020, Myovant is no longer exposed to significant foreign currency
gains or losses.
Net loss for the three months
ended September 30, 2021 was $21.6 million compared to $67.1
million for the comparable prior year period. On a per common share
basis, net loss was $0.23 and $0.75 for the three months ended
September 30, 2021 and 2020, respectively.
Capital resources: Cash, cash
equivalents, marketable securities, and amounts available under the
Sumitomo Dainippon Pharma Loan Agreement totaled $657.3 million as
of September 30, 2021, and consisted of $616.0 million of
cash, cash equivalents, and marketable securities and $41.3 million
of available borrowing capacity under the Sumitomo Dainippon Pharma
Loan Agreement.
Conference CallAs previously
announced, Myovant will hold a webcast and conference call at 8:30
a.m. Eastern Time (5:30 a.m. Pacific Time) today, October 26,
2021, to discuss financial results for its second fiscal quarter
ended September 30, 2021 and corporate updates. Investors and
the general public may access a live webcast of the call by
visiting the investor relations page of Myovant’s website at
investors.myovant.com. Institutional investors and analysts may
also participate in the conference call by dialing 1-800-532-3746
in the U.S. or +1-470-495-9166 from outside the U.S. The webcast
will be archived on Myovant’s Investor Relations website following
the call.
About RelugolixRelugolix is a
once-daily, oral gonadotropin-releasing hormone (GnRH) receptor
antagonist that reduces testicular testosterone, a hormone known to
stimulate the growth of prostate cancer, and ovarian estradiol, a
hormone known to stimulate the growth of uterine fibroids and
endometriosis. ORGOVYX® (relugolix 120 mg) was approved in the U.S.
by the FDA in December 2020 as the first and only oral GnRH
receptor antagonist for the treatment of adult patients with
advanced prostate cancer, and relugolix (120 mg) is also under
regulatory review in Europe for men with advanced prostate cancer.
MYFEMBREE® (relugolix 40 mg, estradiol 1.0 mg, and norethindrone
acetate 0.5 mg) was approved in the U.S. by the FDA in May 2021 as
the first and only once-daily oral treatment for the management of
heavy menstrual bleeding associated with uterine fibroids in
premenopausal women, and by the European Commission and the
Medicines and Healthcare products Regulatory Agency in July 2021
and August 2021, respectively, as RYEQO® for the treatment of
moderate to severe symptoms of uterine fibroids in adult women of
reproductive age. In September 2021, the FDA accepted Myovant
Sciences’ supplemental New Drug Application for MYFEMBREE for the
management of moderate to severe pain associated with
endometriosis, setting a target action date of May 6, 2022.
MYFEMBREE is also being assessed for contraceptive efficacy in
women who are 18 to 50 years of age and at risk for pregnancy.
About Myovant SciencesMyovant
Sciences aspires to redefine care for women and for men through
purpose-driven science, empowering medicines, and transformative
advocacy. Founded in 2016, Myovant Sciences has two FDA-approved
products. ORGOVYX® (relugolix) was approved by the U.S. Food and
Drug Administration in 2020 as the first and only oral
gonadotropin-releasing hormone (GnRH) receptor antagonist for the
treatment of adult patients with advanced prostate cancer, and
relugolix is also under regulatory review in Europe for men with
advanced prostate cancer. Relugolix combination tablet (relugolix
40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) was
approved in 2021 in the U.S. as MYFEMBREE® as the first once-daily
treatment for the management of heavy menstrual bleeding associated
with uterine fibroids in premenopausal women, and by the European
Commission and the Medicines and Healthcare products Regulatory
Agency as RYEQO® for the treatment of moderate to severe symptoms
of uterine fibroids in adult women of reproductive age. Myovant
Sciences filed a supplemental New Drug Application for MYFEMBREE
for the management of moderate to severe pain associated with
endometriosis, which was accepted for review by the FDA in
September 2021. MYFEMBREE is also being assessed for the prevention
of pregnancy. Myovant Sciences is also developing MVT-602, an
oligopeptide kisspeptin-1 receptor agonist, which has completed a
Phase 2a study for female infertility as part of assisted
reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary
of Sumitomo Dainippon Pharma Co., Ltd., is Myovant Sciences’
majority shareholder. For more information, please visit
www.myovant.com. Follow @Myovant on Twitter and LinkedIn.
About Sumitomo Dainippon Pharma Co.,
Ltd.Sumitomo Dainippon Pharma is among the top-ten listed
pharmaceutical companies in Japan, operating globally in major
pharmaceutical markets, including the U.S., Japan, China, and the
European Union. Sumitomo Dainippon Pharma is based on the merger in
2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo
Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has more
than 6,000 employees worldwide. Additional information about
Sumitomo Dainippon Pharma is available through its corporate
website at https://www.ds-pharma.com.
About Sumitovant Biopharma
Ltd.Sumitovant is a global biopharmaceutical company with
offices in New York City and London. Sumitovant is the majority
shareholder of Myovant, and wholly owns Urovant Sciences, Enzyvant
Therapeutics, Spirovant Sciences, and Altavant Sciences.
Sumitovant’s pipeline is comprised of commercialized and
investigational medicines across a range of disease areas targeting
high unmet need. Sumitovant is a wholly owned subsidiary of
Sumitomo Dainippon Pharma. For further information about
Sumitovant, please visit https://www.sumitovant.com.
Forward-Looking Statements This
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. In
this press release, forward-looking statements include, but are not
limited to, all statements reflecting Myovant Sciences’
expectations, including but not limited to: statements regarding
Myovant’s aspiration to redefine care for women and for men;
Myovant’s expectations of the success of commercialization of its
approved drug products; Myovant’s expectation of broad commercial
and Part D coverage for ORGOVYX in calendar-year 2022; the
statement that Myovant remains on track to achieve its goal of
broad coverage for MYFEMBREE within one year of launch; and the
statements under the heading “Expected Upcoming Milestones.”
Myovant Sciences’ forward-looking statements are
based on management’s current expectations and beliefs and are
subject to a number of risks, uncertainties, assumptions, and other
factors known and unknown that could cause actual results and the
timing of certain events to differ materially from future results
expressed or implied by the forward-looking statements, including
unforeseen circumstances or other disruptions to normal business
operations arising from or related to the COVID-19 pandemic.
Myovant Sciences cannot assure you that the events and
circumstances reflected in the forward-looking statements will be
achieved or occur and actual results could differ materially from
those expressed or implied by these forward-looking statements.
Factors that could materially affect Myovant Sciences’ operations
and future prospects or which could cause actual results to differ
materially from expectations include, but are not limited to, the
risks and uncertainties listed in Myovant Sciences’ filings with
the United States Securities and Exchange Commission (SEC),
including under the heading “Risk Factors” in Myovant Sciences’
Quarterly Report on Form 10-Q to be filed on October 26, 2021,
as such risk factors may be amended, supplemented, or superseded
from time to time. These risks are not exhaustive. New risk factors
emerge from time to time and it is not possible for Myovant
Sciences’ management to predict all risk factors, nor can Myovant
Sciences assess the impact of all factors on its business or the
extent to which any factor, or combination of factors, may cause
actual results to differ materially from those contained in any
forward-looking statements. You should not place undue reliance on
the forward-looking statements in this press release, which speak
only as of the date hereof, and, except as required by law, Myovant
Sciences undertakes no obligation to update these forward-looking
statements to reflect events or circumstances after the date of
such statements.
MYOVANT SCIENCES
LTD.Condensed Consolidated Statements of
Operations(Unaudited, in thousands, except share and per
share data)
|
Three Months Ended September 30, |
|
Six Months Ended September 30, |
|
2021 |
|
2020 |
|
2021 |
|
2020 |
Revenues: |
|
|
|
|
|
|
|
Product revenue, net |
$ |
21,063 |
|
|
$ |
— |
|
|
$ |
32,617 |
|
|
$ |
— |
|
Pfizer collaboration revenue |
25,172 |
|
|
— |
|
|
54,681 |
|
|
— |
|
Richter license and milestone revenue |
31,667 |
|
|
— |
|
|
31,667 |
|
|
33,333 |
|
Total revenues |
77,902 |
|
|
— |
|
|
118,965 |
|
|
33,333 |
|
Operating costs and
expenses: |
|
|
|
|
|
|
|
Cost of product revenue |
2,622 |
|
|
— |
|
|
3,654 |
|
|
— |
|
Collaboration expense to Pfizer |
8,565 |
|
|
— |
|
|
13,826 |
|
|
— |
|
Research and development (1) |
26,280 |
|
|
40,521 |
|
|
57,160 |
|
|
84,707 |
|
Selling, general and administrative (1) |
58,781 |
|
|
31,316 |
|
|
119,993 |
|
|
54,144 |
|
Total operating costs and expenses |
96,248 |
|
|
71,837 |
|
|
194,633 |
|
|
138,851 |
|
Loss from operations |
(18,346 |
) |
|
(71,837 |
) |
|
(75,668 |
) |
|
(105,518 |
) |
Interest expense |
3,494 |
|
|
2,115 |
|
|
6,999 |
|
|
4,299 |
|
Interest income |
(100 |
) |
|
(38 |
) |
|
(178 |
) |
|
(146 |
) |
Foreign exchange gain |
— |
|
|
(6,718 |
) |
|
— |
|
|
(10,287 |
) |
Loss before income taxes |
(21,740 |
) |
|
(67,196 |
) |
|
(82,489 |
) |
|
(99,384 |
) |
Income tax (benefit)
expense |
(149 |
) |
|
(134 |
) |
|
762 |
|
|
538 |
|
Net loss |
$ |
(21,591 |
) |
|
$ |
(67,062 |
) |
|
$ |
(83,251 |
) |
|
$ |
(99,922 |
) |
Net loss per common share —
basic and diluted |
$ |
(0.23 |
) |
|
$ |
(0.75 |
) |
|
$ |
(0.90 |
) |
|
$ |
(1.12 |
) |
Weighted average common shares
outstanding — basic and diluted |
92,355,150 |
|
|
89,744,142 |
|
|
92,019,987 |
|
|
89,523,389 |
|
(1) Includes the following share-based compensation: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
$ |
5,060 |
|
|
$ |
3,725 |
|
|
$ |
9,167 |
|
|
$ |
7,749 |
|
Selling, general and
administrative |
6,803 |
|
|
3,199 |
|
|
13,958 |
|
|
6,987 |
|
Total share-based compensation expense |
$ |
11,863 |
|
|
$ |
6,924 |
|
|
$ |
23,125 |
|
|
$ |
14,736 |
|
Revenue components are as follows:
Product revenue, net: |
|
|
|
|
|
|
|
ORGOVYX |
$ |
18,663 |
|
|
$ |
— |
|
|
$ |
29,142 |
|
|
$ |
— |
|
MYFEMBREE |
629 |
|
|
— |
|
|
1,704 |
|
|
— |
|
Richter product supply and royalties |
1,771 |
|
|
— |
|
|
1,771 |
|
|
— |
|
Total product revenue, net |
21,063 |
|
|
— |
|
|
32,617 |
|
|
— |
|
Pfizer collaboration
revenue: |
|
|
|
|
|
|
|
Amortization of upfront payment |
20,974 |
|
|
— |
|
|
41,948 |
|
|
— |
|
Amortization of regulatory milestone |
4,198 |
|
|
— |
|
|
12,733 |
|
|
— |
|
Total Pfizer collaboration revenue |
25,172 |
|
|
— |
|
|
54,681 |
|
|
— |
|
Richter license and milestone
revenue |
31,667 |
|
|
— |
|
|
31,667 |
|
|
33,333 |
|
Total revenues |
$ |
77,902 |
|
|
$ |
— |
|
|
$ |
118,965 |
|
|
$ |
33,333 |
|
MYOVANT SCIENCES
LTD.Condensed Consolidated Balance
Sheets(Unaudited, in thousands)
|
September 30, 2021 |
|
March 31, 2021 |
Assets |
|
|
|
Current assets: |
|
|
|
Cash and cash equivalents |
$ |
518,163 |
|
|
$ |
674,493 |
|
Accounts receivable, net |
14,402 |
|
|
3,570 |
|
Marketable securities |
97,848 |
|
|
10,435 |
|
Inventories |
6,141 |
|
|
2,611 |
|
Prepaid expenses and other current assets |
18,112 |
|
|
13,536 |
|
Total current assets |
654,666 |
|
|
704,645 |
|
Property and equipment,
net |
3,297 |
|
|
3,300 |
|
Operating lease right-of-use
asset |
8,835 |
|
|
9,655 |
|
Other assets |
12,742 |
|
|
7,427 |
|
Total assets |
$ |
679,540 |
|
|
$ |
725,027 |
|
Liabilities and
Shareholders’ Deficit |
|
|
|
Current liabilities: |
|
|
|
Accounts payable |
$ |
8,642 |
|
|
$ |
17,809 |
|
Accrued expenses and other current liabilities |
46,334 |
|
|
44,612 |
|
Share-based compensation liabilities |
5,769 |
|
|
21,636 |
|
Deferred revenue |
100,564 |
|
|
100,564 |
|
Amounts due to Pfizer |
19,957 |
|
|
1,954 |
|
Cost share advance from Pfizer |
84,768 |
|
|
92,415 |
|
Operating lease liability |
1,968 |
|
|
1,807 |
|
Amounts due to related parties |
334 |
|
|
543 |
|
Total current liabilities |
268,336 |
|
|
281,340 |
|
Deferred revenue,
non-current |
426,021 |
|
|
397,369 |
|
Cost share advance from
Pfizer, non-current |
— |
|
|
29,447 |
|
Long-term operating lease
liability |
8,159 |
|
|
9,189 |
|
Long-term debt, less current
maturities (related party) |
358,700 |
|
|
358,700 |
|
Other liabilities |
1,251 |
|
|
2,947 |
|
Total liabilities |
1,062,467 |
|
|
1,078,992 |
|
Total shareholders’ deficit |
(382,927 |
) |
|
(353,965 |
) |
Total liabilities and
shareholders’ deficit |
$ |
679,540 |
|
|
$ |
725,027 |
|
Investor Contact: Ryan CroweVice President,
Investor RelationsMyovant Sciences, Inc. +1 (650)
781-9106investors@myovant.com
Media Contact:Albert LiaoDirector, Corporate
CommunicationsMyovant Sciences, Inc.+1 (650)
410-3055media@myovant.com
Myovant Sciences (NYSE:MYOV)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Myovant Sciences (NYSE:MYOV)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024